Glioma

Global Glioma Therapeutics Market 2019-2023

Retrieved on: 
Thursday, January 3, 2019
Brain tumor, Glioma

Technavio' s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.

Key Points: 
  • Technavio' s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.
  • Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.
  • For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view our report.
  • Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures.

DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

Retrieved on: 
Monday, November 26, 2018
Cancer, Medicine, Brain tumor, Virotherapy, Oncolytic virus, Diffuse intrinsic pontine glioma, CD134, Glioma, Pembrolizumab, Glioblastoma

HOUSTON, Nov. 26, 2018 /PRNewswire/ -- DNAtrix , a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L).

Key Points: 
  • HOUSTON, Nov. 26, 2018 /PRNewswire/ -- DNAtrix , a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L).
  • For more information about ongoing DNAtrix clinical studies, visit the ClinicalTrials.gov website: NCT03714334 (DNX-2440 for recurrent glioblastoma), NCT02798406 (DNX-2401 with pembrolizumab for recurrent glioblastoma), and NCT03178032 (DNX-2401 for newly diagnosed pediatric diffuse intrinsic pontine glioma, DIPG).
  • DNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer.
  • DNAtrix has multiple virus candidates in clinical trials for cancers with urgent needs for novel approaches.

Shakti Ramkissoon's Research in Genomic Profiling of Pediatric Tumors Earns Him the Oncologist's Inaugural Young Investigator Award

Retrieved on: 
Monday, November 12, 2018
Brain tumor, Glioma

DURHAM, N.C., Nov. 12, 2018 /PRNewswire-PRWeb/ --Shakti H. Ramkissoon, MD, PhD, MMSc, was awarded The Oncologist's inaugural Young Investigator Award for his work on genomic profiling in children with brain tumors.

Key Points: 
  • DURHAM, N.C., Nov. 12, 2018 /PRNewswire-PRWeb/ --Shakti H. Ramkissoon, MD, PhD, MMSc, was awarded The Oncologist's inaugural Young Investigator Award for his work on genomic profiling in children with brain tumors.
  • Dr. Ramkissoon obtained his MD, PhD from Rutgers - New Jersey Medical School and is a board-certified neuropathologist with expertise in adult and pediatric brain tumors.
  • Dr. Ramkissoon currently serves as the Medical Director for FMI operations at the Research Triangle Park facility in North Carolina.
  • Read the winning paper Comprehensive Genomic Profiling of 282 Pediatric Low and HighGrade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.

American Brain Tumor Association's Statement on the Passing of Senator McCain and the Disease that Took His Life

Retrieved on: 
Tuesday, August 28, 2018
Brain tumor, Cancer, RTT, Oncology, American Brain Tumor Association, Glioblastoma, Astrocytoma, Glioma

CHICAGO, Aug. 28, 2018 /PRNewswire/ --The American Brain Tumor Association (ABTA) is saddened to learn about the passing of war hero and United States Senator John McCain.

Key Points: 
  • CHICAGO, Aug. 28, 2018 /PRNewswire/ --The American Brain Tumor Association (ABTA) is saddened to learn about the passing of war hero and United States Senator John McCain.
  • Glioblastoma represents about 15 percent of all brain tumors (both malignant and non-malignant) and about 47 percent of malignant brain tumors.
  • Glioblastoma is considered to be the deadliest brain tumor, with the average life expectancy after diagnosis being between 11 and 15 months.
  • Celebrating 45 years of impact on the brain tumor community, the American Brain Tumor Association was the first national patient advocacy organization committed to funding brain tumor research and providing support and education programs for patients, caregivers and their loved ones.

Promising Treatment of Challenging Pediatric Brain Stem Tumor, DIPG, with Alcyone AMC Precision Delivery of Oncolytic Adenovirus

Retrieved on: 
Tuesday, July 3, 2018
Adenoviridae, Medicine, Biotechnology, Experimental cancer treatments, Virotherapy, Oncolytic adenovirus, Oncolytic virus, Biology, Glioma, Cannula

There is no effective treatment, and due to the very challenging anatomical location of the tumor, surgical resection is often not possible, and effective intratumoral drug infusion can be challenging.

Key Points: 
  • There is no effective treatment, and due to the very challenging anatomical location of the tumor, surgical resection is often not possible, and effective intratumoral drug infusion can be challenging.
  • "With technical support from Alcyone, Ricardo Diez Valle, MD, PhD, and our neurosurgical team have been able to consistently and safely use the AMC for precision delivery of the oncolytic adenovirus in very difficult to reach brain stem tumors in six pediatric DIPG patients with no observed grade 3 or 4 adverse events.
  • "The safe and precise delivery of oncolytic adenovirus with the AMC directly into the pontine glioma shows great potential in enabling the treatment of these pediatric patients, who until now have had no viable options.
  • About Alcyone's MEMS Cannula (AMC) Targeted Delivery System:
    The Alcyone MEMS Cannula (AMCTM) Targeted Delivery System was developed using the company's proprietary microelectromechanical system (MEMS) technology platform.

Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology

Retrieved on: 
Monday, July 2, 2018
Brain tumor, Glioma, Oncolytic adenovirus, Oncolytic virus, Medicine, Radiation therapy, Biology, Clinical medicine

Dr. Tejada will report that DNX-2401 can be administered safely to the pons in the brainstem of pediatric patients prior to radiotherapy, with minimal side effects.

Key Points: 
  • Dr. Tejada will report that DNX-2401 can be administered safely to the pons in the brainstem of pediatric patients prior to radiotherapy, with minimal side effects.
  • "We have treated six pediatric DIPG patients with DNX-2401 and observed no grade 3 or 4 adverse events, indicating that this a safe therapy for pediatric patients with brain tumors.
  • Based on these updated results, we intend to test DNX-2401 in a range of brain tumors that affect children," said Sonia Tejada, MD, PhD.
  • DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus currently being evaluated in clinical trials for adult and pediatric malignant gliomas, brain cancers for which there are no adequate treatments.